



SEPTEMBER, 2021

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

FOREWORD

Rwanda Food and Drugs Authority (Rwanda FDA) is a regulatory body established by the Law N° 003/2018 of 09/02/2018. One of the functions of Rwanda FDA is to regulate matters related to quality, safety and efficacy of human medicinal products in order to protect public health by increasing access and availability of essential medicines.

Considering the provisions of the technical Regulations N° CBD/TRG/010 Governing the registration of human medicinal products especially in its articles 6, 7, 8, 9, 12 and 32, and the Guidelines No DHT/GDL/001 on submission of documentation for registration of human medicinal products, the Authority has to issue the Guidance N°: DAR/GDL/001K on naming of Human Medicinal Products

Rwanda FDA adopted the Common Technical Document (CTD) Guidelines on Submission of Documentation for registration of human medicinal products. These guidelines have been developed to provide guidance to the applicants and the Authority in managing applications for registration of human medicinal products. These guidelines were developed in reference to the existing Ministry of Health (MOH) guidelines on submission of documentation for registration of Human Pharmaceutical Products which were domesticated based on Compendium of Medicines Evaluation and Registration for Medicines Regulation Harmonization in the East African Community, World Health Organization (WHO) and the International Conference on Harmonization of Technical Requirements for Registration of Medicines for Human Use (ICH) and other available literature.

The Authority acknowledges all the efforts of key stakeholders who participated in the development and validation of these guidelines.

Emile Bienvenu
Dr Emile BIENVENU
Director General



Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

1. TABLE OF CONTENTS

FOREWORD	2
1. TABLE OF CONTENTS	3
2. INTRODUCTION	4
3. SCOPE	4
4. ACKNOWLEDGMENTS	4
5. CRITERIA APPLIED WHEN REVIEWING PROPOSED BRAND NAMES	4
6. REGULATORY ASPECTS RELATED TO THE ACCEPTABILITY OF PROPOSED BRAND NAMES	10
6.1. Change of the brand name	10
6.2. Report of prescription errors/medication errors due to the brand names of medicinal products:	11
7. REFERENCES	11
8. DOCUMENT REVISION HISTORY	11



RWANDA FDA
Rwanda Food and Drugs Authority

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

2. INTRODUCTION

Prescription and medication error may occur partly due to medicinal products having sound-alike or look-alike brand names, unclear labelling or poorly designed label artwork. Hence this guideline was developed in order to provide Applicants with clear guidance on how to choose brand names for their medicinal products.

Rwanda FDA may request changes to a brand name if based on evaluation, it is deemed to potentially:

- cause confusion with the name of an existing medicine;
- mislead as to the composition of the product or the use;
- or otherwise unsafe.

Approval of the name does not imply that the marketing authorization holder is absolved of any responsibility in the incidence that actual or potential adverse reactions occur due to the brand name.

Individual Partner States legislations in particular trade laws, should be taken into consideration while proposing a specific brand name.

3. SCOPE

This guideline is applicable to all prescription and non-prescription medicinal products as well as medicinal products of biological origin.

The principles outlined in this guideline are also applicable for applications for variation of names of registered medicinal products.

4. ACKNOWLEDGMENTS

This guideline was developed based on the European Medicines Agency's Guideline on the acceptability of names for human medicinal products processed through the centralized procedure.

5. CRITERIA APPLIED WHEN REVIEWING PROPOSED BRAND NAMES

The criteria listed below should be seen as general principles. Rwanda FDA may develop additional guidance on specific topics based on experience and may apply additional requirements not listed in this document during review of proposed brand names.

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

The criteria for acceptability of proposed brand names shall be based on public health concerns and in particular with regard to safety.

Applicants should ensure that the proposed name complies with the criteria outlined in this guideline before submitting an application for marketing authorization. Requirements and considerations taken during review are outlined hereafter:

5.1. Safety concerns and other public health concerns in brand names

5.1.1. The brand name of a medicinal product should not be liable to cause confusion in print, handwriting or speech with the brand name of another medicinal product.

When assessing the potential for such confusion, the following aspects are considered:

- The indication(s);
 - The patient population(s);
 - The pharmaceutical form(s);
 - The route(s) of administration;
 - The strength(s);
 - The setting for prescription, dispensing and use;
 - The legal status/classification for supply:
 - Medicinal product subject to medical prescription;
 - Medicinal product not subject to medical prescription;
 - Medicinal product subject to special medical prescription;
 - Medicinal product subject to restricted medical prescription;
 - Medicinal product subject to special and restricted medical prescription;
 - Orphan (designation) status;
 - (Potential) New pharmaceutical forms, routes of administration and/or strengths for the medicinal product concerned, as appropriate.
-
- The degree of similarity versus the potential for harm to the patient in case of mix-up.

It should be noted that Rwanda FDA will consider potential for confusion of proposed brand names with the brand names of authorized, suspended and revoked/withdrawn medicinal products in the different Partner States according to the relevant national legislation regardless of the route of authorization.

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

When considering potential for confusion with the name of a withdrawn/revoked marketing authorization, in principle, a period of 5 years should have elapsed after the official invalidity of the marketing authorization according to national legislation (e.g. publication in the national gazette notice, etc.). This period could be reduced (e.g. the product was not marketed in Rwanda for a period preceding this 5-year period) if it can reasonably be justified by the Applicant. The period may be extended (e.g. that the withdrawal of the marketing authorization was linked to serious safety concerns and this has an impact on the potential risk to public health associated with the name) at the discretion of Rwanda FDA. Rwanda FDA may also consider potential safety concerns and other public health concerns associated to the re-use of identical brand names.

- 5.1.2. The brand name of a human medicine should not convey misleading therapeutic and/or pharmaceutical connotations. This also includes brand names that are similar or allude to the name of pharmaceutical companies if they are thought to be misleading and cause confusion at the level of product information.
- 5.1.3. The brand name of a human medicine should not be misleading with respect to the composition of the product.
- 5.1.4. Consideration should be given to the phonetics and the potential difficulties a proposed brand name may create in terms of pronunciation in the official languages in Rwanda. Consideration should also be given to the fact that very short brand names composed of, for instance, a string of letters, may be inappropriate to identify human medicines in the country.
- 5.1.5. The use of qualifiers/abbreviations by letters as part of the brand name should in principle be acceptable on conditions.

Qualifiers consisting of a single letter or number(s) (Arabic and Roman) are discouraged, because they may be confused with the strength and/or posology of the medicinal product. However, the use of numbers may in certain cases be acceptable, e.g. vaccines (see section 4.3.1). The applicant may provide a justification for their inclusion.

The potential added benefit versus its potential risk to public health in case of medication error shall be taken into consideration when considering the acceptability of a qualifier/abbreviation.

The following shall be considered:

- a) Whether the qualifier/abbreviation provides further information on characteristics of the medicinal product (e.g. duration of action, devices, route of administration, composition, patient population) without being misleading or provides for a

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

- differentiation, which may help healthcare professionals and/or patients to prescribe/select the appropriate medicinal product.
- b) The applicability and use of the qualifier across all official languages. Qualifiers or abbreviations should not require translation to provide further information.
 - c) The potential risk resulting from more complex names, adversely affecting memorability, pronunciation and/or prescription of the medicinal product.
- 5.1.6. The brand name should not convey a promotional message with respect to the therapeutic and/or pharmaceutical characteristics and/or the composition of the medicinal product.
- 5.1.7. The brand name should not be offensive or have an inappropriate connotation in any of the official languages.
- 5.1.8. For a medicinal product containing a prodrug, a different brand name from the brand name of the medicinal product containing the related active substance is required.
- 5.1.9. The brand name should not comprise wholly of initial letters (acronyms) or code numbers nor include punctuation marks.
- 5.1.10. The importance of other elements such as labelling and pack design should be taken into consideration as contributing factors for the safe use of a medicinal product. These aspects should be discussed at the time of the review of mock-ups.

The following are examples where labelling and pack design may play a role in the final decision of acceptability of brand names:

- a) The actual display of a brand name in the printed material may increase the level of similarity between two brand names or may convey a misleading connotation.
- b) The labelling and pack design may support the meaning of a qualifier which otherwise would have been rejected.

5.2. Use of international non-proprietary names in proposed brand names

When proposing a brand name, Applicants are advised to take into consideration WHO resolution (WHA46.19), where appropriate, i.e. "It would therefore be appreciated if brand names were not derived from international non-proprietary names (INNs) and if INN stems were not used in brand names".

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

Two types of INN concerns could be considered i.e. a potential similarity with its own or different INN or the inclusion of an INN stem into the proposed brand name(s).

The Applicant is strongly advised to review INN similarity and/or INN stem inclusion before requesting that the proposed brand name(s) be considered for a medicinal product.

Rwanda FDA will review the above cases on the basis of WHO World Health Assembly resolution (WHA46.19) on protection of INNs/INN stems to prevent any potential risk of confusion between brand names and common names.

5.3.Product specific concerns in proposed brand names

5.3.1. For vaccines composed of several serotypes, when adding a new serotype, the original brand name may be kept, it is recommended that the name is then followed by the number of serotypes present. The description of serotypes present is then listed in the qualitative and quantitative composition. An example of the format of the proposed brand name follows:

Brand name + X [number of serotypes]

The same applies when different types of antigens are added. This is of particular importance in situations where both vaccines are simultaneously available on the market in order to allow differentiation of the products.

5.3.2. For radiopharmaceutical medicinal products, the inclusion of target organs in the brand name should be avoided in order to prevent misleading connotations should an extension of the indication include new target organs. In principle, numbers should not be used in the name to avoid confusion with the strength. In cases where the numbers appear in the radionuclide, these should be displayed in superscript, i.e.mass number Element + [brand name]. Numbers included as part of commonly known abbreviations will be assessed on a case by case basis.

5.3.3. When reviewing the acceptability of brand names for orphan medicinal products, the same approach as for non-orphan medicinal products shall be applied. It is of particular importance in these cases to provide detailed information on the specific setting in which the product is dispensed and used as well as on the target population.

5.3.4. For non-prescription medicinal products, the use of qualifiers/abbreviations within the brand name should aid selection/identification/differentiation of the product by the patient and should minimize the risk of inappropriate use.

In view of the above considerations, the specific criteria as described under sections 5.1.5, 5.1.8 and 5.3.7 may not apply here.

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

In order to help self-selection and compliance by patients/consumers, it is acceptable that brand names have a positive connotation and/or be informative; labelling and pack design could be considered as contributing factors to this end. Carton and container labels are particularly critical for non-prescription medicinal products (general sale and OTC).

In case of a switch from "prescription" to "non-prescription" status of an already authorized medicinal product it is up to the Applicant to choose whether to vary/extend the existing marketing authorization and consequently retain the same brand name or to submit a separate marketing-authorization application under a different brand name (see section 5). In exceptional cases, depending on the therapeutic context, the acceptability of the maintenance of the existing brand name may be further considered by Rwanda FDA during the evaluation process.

5.3.5. For generic/hybrid/similar biological medicinal products the same criteria apply as for any other medicinal products in respect to the brand name.

Special consideration should be given to the proposed brand name of a hybrid medicinal product to allow for differentiation when the latter differs in pharmaceutical form, strength, expression of active substance and/or indication from the reference medicinal product or other generics in the market.

5.3.6. Where the Applicant wishes to use instead of the brand name the common name or scientific name, together with a trademark or the name of the marketing-authorization holder/applicant, they should take into account the following rules:

- a. If an INN recommended by the World Health Organization exists for the active moiety it should be used within the name of the medicinal product exactly as published without omissions or abbreviations. All the linguistic versions of the INN, including translations officially recognized at the national level, shall be considered to be the same name. If one does not exist, the usual common name should be used.
- b) If a Modified INN (INNM) recommended by the World Health Organization exists for the active moiety, it should be used within the name of the medicinal product exactly as published without omissions or abbreviations.
- c) Where the active moiety is an unpublished INNM the name of the medicinal product should be that as agreed by users of INNs (pharmacopoeia, regulatory bodies, stakeholders), in accordance with the WHO INNM working document 05.167/3.

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

- d) The 'name of the MAH' within the name of the medicinal product should correspond to all or part of the official name of the MAH as presented in the proof of establishment of the applicant/MAH.
 - e) For consistency reasons, ease in prescription by healthcare professionals and database entries, punctuation marks in between the INN and the name of the Company/trademark are not acceptable (with the exception of fixed combinations, where multiple INNs should be clearly separated by slash '/').
 - f) The proposed brand name should either be a brand name or the common name accompanied by a trademark or the name of the MAH.
- 5.3.7. The brand name of a fixed dose combination of medicinal product should be sufficiently different from those of the individual active substances and/or those of other fixed combinations containing the same active substance(s).
- The whole brand name of individual active substance(s) should not be inserted into the proposed brand name for the fixed dose combination.
- 5.3.8. As multiple applications can have an independent life (e.g. may develop a different indication at a later stage), the proposed brand names of such applications should not lead to confusion.

6. REGULATORY ASPECTS RELATED TO THE ACCEPTABILITY OF PROPOSED BRAND NAMES

Brand names for variation/extension/duplicate applications should be the same as those of the existing medicinal product. The addition of a qualifier to an already approved brand name constitutes a different brand name, which would require submission as new marketing authorization application.

In case the applicant wants to submit a separate marketing-authorization application for, e.g., a new indication, a different brand name shall be used.

Rwanda FDA may request the MAH to change the brand name of an already approved medicinal product if the approved brand name is deemed inappropriate.

6.1. Change of the brand name

The brand name can also be changed at a post-authorizations stage through an application for variation if the MAH wishes to change the name.

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	

Post-authorizations procedural requirements are outlined in the Guidelines on Variations on Registered Medicinal Products.

6.2. Report of prescription errors/medication errors due to the brand names of medicinal products:

The marketing authorization holder is responsible for reporting any adverse drug reactions resulting from: -

Prescription errors/medication errors due to the brand name of the medicinal product (example mix up with another medicinal product resulting into an ADR).

Misuse and/or abuse of a medicinal product caused by misleading therapeutic connotations of the brand name.

The ADRs should be reported in accordance to the procedures and guidance stipulated in the Rwanda FDA guidelines on Safety and Vigilance of Medical Products and Health technologies.

7. REFERENCES

1. Guideline on the acceptability of names for human medicinal products processed through centralized procedure
2. WHO website: <http://www.who.int/en/>
3. Information on INNs: <http://apps.who.int/medicinedocs/en/d/Jh1806e/5.html>

8. DOCUMENT REVISION HISTORY

Date of Revision	Revision Number	Document Number	Change Made
03/09/2021	Rev_0	DAR/GDL/001K	First Issue

RWANDA FDA
Rwanda Food and Drugs Authority

End of document

Doc. No.: DAR/GDL/001K	Revision Date: 25/08/2021	Review Due Date: 03/09/2024
Revision No.: 0	Effective Date: 03/09/2021	